111 related articles for article (PubMed ID: 23673111)
1. Correlations between papillary thyroid cancer and peripheral blood levels of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2.
Zhou SF; Hu SY; Ma L; Miao L; Mao WZ
Chin Med J (Engl); 2013; 126(10):1925-9. PubMed ID: 23673111
[TBL] [Abstract][Full Text] [Related]
2. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H
Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633
[TBL] [Abstract][Full Text] [Related]
4. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
5. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
6. Circulating matrix metalloproteinases and their inhibitors in inguinal hernia and abdominal aortic aneurysm.
Antoniou GA; Tentes IK; Antoniou SA; Georgiadis GS; Giannoukas AD; Simopoulos C; Lazarides MK
Int Angiol; 2011 Apr; 30(2):123-9. PubMed ID: 21427648
[TBL] [Abstract][Full Text] [Related]
7. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
[TBL] [Abstract][Full Text] [Related]
8. [Correlations of serous levels of matrix metalloproteinases (MMP-2 and MMP-9) to invasion and metastasis of papillary thyroid carcinoma].
Yu HZ; Li ZP; Li SG; Wu CM
Ai Zheng; 2005 Jun; 24(6):740-2. PubMed ID: 15946492
[TBL] [Abstract][Full Text] [Related]
9. Assessment of gelatinase and tumor necrosis factor-α level in the vitreous and serum of patients with Eales disease: role of inflammation-mediated angiogenesis in the pathogenesis of Eales disease.
Sen A; Paine SK; Chowdhury IH; Mukherjee A; Choudhury S; Mandal LK; Bhattacharya B
Retina; 2011; 31(7):1412-20. PubMed ID: 21394064
[TBL] [Abstract][Full Text] [Related]
10. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
11. Serum matrix metalloproteinases and tympanosclerosis.
Aslan H; Başoğlu MS; Sentürk B; Ozbay C; Katilmiş H; Oztürkcan S
J Laryngol Otol; 2011 Feb; 125(2):142-6. PubMed ID: 20955636
[TBL] [Abstract][Full Text] [Related]
12. [Detection and molecular staging of bladder cancer using real-time RT-PCR for gelatinases (MMP-2, MMP-9) and TIMP-2 in peripheral blood].
Angulo JC; Ferruelo A; Rodríguez-Barbero JM; Núñez C; de Fata FR; González J
Actas Urol Esp; 2011 Mar; 35(3):127-36. PubMed ID: 21334102
[TBL] [Abstract][Full Text] [Related]
13. [Comment to: "Detection and molecular staging of bladder cancer using real-time RT-PCR for gelatinases MMP-2, MMP-9 and TIMP-2 in peripheral blood"].
López JI
Actas Urol Esp; 2011 Mar; 35(3):137. PubMed ID: 21334101
[No Abstract] [Full Text] [Related]
14. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
15. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass].
Paśnik J; Cywińska-Bernas A; Moll J; Moll J; Sysa A; Zeman K
Przegl Lek; 2009; 66(7):359-64. PubMed ID: 20043576
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[TBL] [Abstract][Full Text] [Related]
17. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
18. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
19. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
20. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
